Skip to main content
main-content

The independent medical news service

Kidney cancer

08-04-2020 | Oncology | News | Article

Tocilizumab shows promise for COVID-19 treatment in people with cancer

The interleukin-6 receptor inhibitor tocilizumab warrants further investigation for the treatment of COVID-19 in patients with cancer, say the authors of a case report.

02-03-2020 | Oncology | News | Article

Cytoreductive nephrectomy ‘still plays a role’ for metastatic RCC

Cytoreductive nephrectomy continues to offer a significant overall survival benefit for carefully selected patients with metastatic renal cell carcinoma in the era of immune checkpoint inhibitor and targeted therapies, a propensity score-based analysis indicates.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

02-03-2020 | Oncology | News | Article

Updated CheckMate 214 analysis confirms nivolumab–ipilimumab RCC benefit

CheckMate 214 data presented at the 2020 Genitourinary Cancers Symposium show the continued benefit of combination treatment with nivolumab plus ipilimumab over sunitinib in individuals with treatment-naïve advanced renal cell carcinoma.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

28-02-2020 | Oncology | News | Article

Drug targeting HIF-2α ‘well-tolerated’ in advanced clear-cell RCC

MK-6482, a first-in-class hypoxia-inducible factor-2α inhibitor, has a favorable safety profile and demonstrates clinical activity in patients with advanced clear-cell renal cell carcinoma, phase 1/2 trial data suggest.

27-02-2020 | Oncology | News | Article

Sitravatinib may boost nivolumab efficacy in advanced clear-cell RCC

Adding sitravatinib to nivolumab results in a higher response rate and longer disease control in patients with advanced clear-cell renal cell carcinoma than has historically been achieved with nivolumab monotherapy, with no unacceptable toxicity, research shows.

21-02-2020 | Oncology | News | Article

Durvalumab–savolitinib duo has potential in metastatic papillary renal cell carcinoma

Patients with metastatic papillary renal cell carcinoma are likely to benefit from the durvalumab–savolitinib combination, show findings from the 1-year follow-up of the CALYPSO trial.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

18-02-2020 | Oncology | News | Article

Further investigation of combined immunotherapy, SBRT may be warranted for mRCC

Findings from two phase 2 trials suggest that combining immune checkpoint inhibition with stereotactic body radiotherapy is feasible in patients with metastatic renal cell carcinoma.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

08-01-2020 | Oncology | News | Article

PD-1 inhibition may result in better solid tumor survival than PD-L1 inhibition

Treatment with PD-1 inhibitors offers better overall survival, with comparable tolerability, than does treatment with PD-L1 inhibitors for patients with solid tumors such as non-small-cell lung cancer, suggests a systematic review and meta-analysis.

07-01-2020 | Oncology | News | Article

Tumor microenvironment changes implicated in clear cell RCC obesity paradox

Tumors from obese patients with clear cell renal cell carcinoma have higher angiogenesis scores than those from normal-weight patients, as well as differences in the tumor microenvironment, US researchers report.

13-12-2019 | Oncology | News | Article

Sarcopenia could predict the immune-related toxicity risk associated with nivolumab

Sarcopenia in cancer patients taking nivolumab is associated with an increased risk for immune-related acute limiting toxicity, independent of plasma nivolumab concentrations, study results suggest.

21-11-2019 | Oncology | News | Article

Data support immunotherapy combination for RCC with variant histology, sarcomatoid features

A meaningful proportion of patients with advanced renal cell carcinoma with variant histology or sarcomatoid differentiation respond to the immunotherapy combination of atezolizumab and bevacizumab without experiencing severe toxicity, phase II study data show.

22-10-2019 | Oncology | News | Article

Benefit of nivolumab–tivozanib, nivolumab beyond progression shown in metastatic RCC

Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.

21-10-2019 | Oncology | News | Article

Treatment-free survival proposed as novel RCC immunotherapy endpoint

Time spent off treatment could be used as a novel clinical trial endpoint for patients undergoing renal cell carcinoma immunotherapy, suggest study findings reported at the ESMO Congress 2019 in Barcelona, Spain.

18-10-2019 | Oncology | News | Article

KEYNOTE-427 updates confirm pembrolizumab benefit for advanced RCC

The latest findings from the KEYNOTE-427 trial add to the efficacy evidence for first-line pembrolizumab against advanced or metastatic renal cell carcinoma regardless of histology.

17-10-2019 | Oncology | News | Article

Neoadjuvant nivolumab tested for metastatic RCC

Results from the ADAPTeR study suggest that giving nivolumab before and after cytoreductive nephrectomy or metastatic biopsy may be a feasible strategy for patients with treatment-naïve metastatic clear cell renal cell carcinoma.

15-10-2019 | Oncology | News | Article

TITAN-RCC showcases tailored immunotherapy approach

Results from the TITAN-RCC trial add support for the use of ipilimumab alongside nivolumab in patients with intermediate- or high-risk advanced renal cell carcinoma, showing that a personalized strategy is feasible for nonresponders.

14-10-2019 | Oncology | News | Article

SORCE rules out adjuvant sorafenib for RCC

Sorafenib should not be used in the adjuvant setting in patients with resected renal cell carcinoma at intermediate or high risk of relapse, says the SORCE research team.

08-10-2019 | Oncology | News | Article

JAVELIN Renal 101 subanalyses add to evidence for avelumab plus axitinib

Findings from the JAVELIN Renal 101 trial of patients with advanced renal cell carcinoma suggest front-line use of avelumab plus axitinib is superior to sunitinib for patients with sarcomatoid histology and for those who did not undergo upfront cytoreductive nephrectomy.

25-09-2019 | Oncology | News | Article

Avelumab indication extended in Europe to advanced RCC

Find out more here

02-09-2019 | Oncology | Main feed | Article

Elevated cardiovascular risk seen in survivors of most common cancers

Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.

Image Credits